Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Peptide hormone ELABELA promotes rat bone marrow-derived mesenchymal stem cell proliferation and migration by manipulating the cell cycle through the PI3K/AKT pathway under the hypoxia and ischemia microenvironment

Fig. 2

The impact of ELA on the cell cycle progression under H/I conditions for 24 h. The treatment time of ELA (at a concentration of 5 μM) was 12 h prior to H/I injury. A The representative results of the cell cycle. B The percentage of S and G2/M phases of RAT BM-MSCs. C The percentage of cell cycle distributions of RAT BM-MSCs involving G0/G1, S, and G2/M. *P < 0.05. ELA, ELABELA; RAT BM-MSCs, Rat bone marrow-derived mesenchymal stem cells; H/I, hypoxic-ischemic; LY, LY294002

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512